ACM
AVBP icon

AIHC Capital Management’s ArriVent BioPharma AVBP Stock Holding History

AIHC Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-644,788
Closed -$13M – 7
2025
Q4 		$13M Buy
+644,788
New +$13.4M 12.16% 3

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AIHC Capital Management's AVBP Position: Q1 2026 in Review

AIHC Capital Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 644,788 shares — an estimated $13M sold.

AIHC Capital Management first reported a position in AVBP in Q4 2025 and held it in 1 quarter. The position peaked at $13M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • AIHC Capital Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • AIHC Capital Management sold 644,788 ArriVent BioPharma shares in Q1 2026, an estimated $13M.
  • AIHC Capital Management first reported a position in ArriVent BioPharma in Q4 2025 and held it in 1 quarter.
  • AIHC Capital Management's ArriVent BioPharma position peaked at $13M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on AIHC Capital Management's 13F filing for Q1 2026, filed 8 May 2026.